Poorly-performed osteoporosis market

Published: 2016-05-10 14:49:17

Updated: 2016-05-10 14:49:17

Bisphosphonate(BP) drugs, osteoporosis treatments that are known to have particular administration, have recorded poor performances.

On the other hand, SERM-type drugs have become the only drugs which showed potentials in the falling osteoporosis market. The uptrend of ‘Evista,’ the first SERM-type drug, has been weakened due to launches of other competing drugs.

According to the analysis res...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.